ATE339961T1 - Chromium/biotin behandlung von dyslipidemia - Google Patents

Chromium/biotin behandlung von dyslipidemia

Info

Publication number
ATE339961T1
ATE339961T1 AT02721275T AT02721275T ATE339961T1 AT E339961 T1 ATE339961 T1 AT E339961T1 AT 02721275 T AT02721275 T AT 02721275T AT 02721275 T AT02721275 T AT 02721275T AT E339961 T1 ATE339961 T1 AT E339961T1
Authority
AT
Austria
Prior art keywords
chromium
biotin
dyslipidemia
mug
biotin treatment
Prior art date
Application number
AT02721275T
Other languages
English (en)
Inventor
James R Komorowski
La Harpe Jon De
Danielle Greenberg
Vijaya Juturu
Original Assignee
Nutrition 21 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 Inc filed Critical Nutrition 21 Inc
Application granted granted Critical
Publication of ATE339961T1 publication Critical patent/ATE339961T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02721275T 2001-02-27 2002-02-27 Chromium/biotin behandlung von dyslipidemia ATE339961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27188101P 2001-02-27 2001-02-27

Publications (1)

Publication Number Publication Date
ATE339961T1 true ATE339961T1 (de) 2006-10-15

Family

ID=23037476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721275T ATE339961T1 (de) 2001-02-27 2002-02-27 Chromium/biotin behandlung von dyslipidemia

Country Status (10)

Country Link
US (2) US20020197331A1 (de)
EP (1) EP1397148B1 (de)
JP (1) JP2004521127A (de)
CN (1) CN1512887A (de)
AT (1) ATE339961T1 (de)
CA (1) CA2438063A1 (de)
DE (1) DE60214849T2 (de)
ES (1) ES2271242T3 (de)
PT (1) PT1397148E (de)
WO (1) WO2002067953A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043106A1 (en) * 2002-08-28 2004-03-04 Anfinsen Jon R. Methods and systems for determining and controlling glycemic responses
WO2004047765A2 (en) * 2002-11-22 2004-06-10 Shaklee Corporation Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
RU2261704C2 (ru) * 2003-02-11 2005-10-10 Кобелев Константин Викторович Способ антимутагенного воздействия на организм
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
WO2007065444A1 (en) * 2005-12-09 2007-06-14 Saibot Aps A method for evaluating the potential of a compound for use in therapy
RU2449554C2 (ru) * 2006-02-01 2012-05-10 Нестек С.А. Пищевые системы и способы увеличения долголетия
WO2007121312A2 (en) 2006-04-12 2007-10-25 Interhealth Nutraceuticals, Inc. Trivalent chromium compounds, compositions and methods of use
TW200829178A (en) * 2006-09-07 2008-07-16 Abbott Lab Controlled glycemic response sweetened cereal product
US20130071491A1 (en) * 2006-12-18 2013-03-21 Jose De J. Berrios Extruded Legume Food Products Containing Yeast Autolysate
CA3021932C (en) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Use of chromium histidinate for treatment of cardiometabolic disorders
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
ES2395529B1 (es) * 2011-06-08 2014-04-11 Pri, S.A. Combinación sinérgica para el tratamiento de la diabetes mellitus tipo 2.
US20150258078A1 (en) * 2014-03-12 2015-09-17 Alexander R. Shikhman Compositions containing berberine and pantethine and methods for treatment of lipid metabolism disorders
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
JP6932689B2 (ja) * 2016-04-14 2021-09-08 テーブルマーク株式会社 血糖値低下用又はｇｉ値低減用の食品組成物又は組み合わせ

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1234567A (en) * 1915-09-14 1917-07-24 Edward J Quigley Soft collar.
USRE33988E (en) * 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
JPS5927833A (ja) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5032608A (en) * 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4921877A (en) * 1986-10-27 1990-05-01 Abbott Laboratories Liquid nutritional formula for glucose intolerance
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5175156A (en) * 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
US5087624A (en) * 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5106836A (en) * 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5114963A (en) * 1991-03-13 1992-05-19 Medicis Corporation Method of reducing serum levels of lipoprotein(A)
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
US5937597A (en) * 1996-07-18 1999-08-17 Ykk Architectural Products Inc. Multi-window sash and batten attachment structure
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
HUP0003713A2 (hu) * 1997-08-08 2001-04-28 Nutrition 21 Króm és biotin tartalmú gyógyászati készítmény II típusú diabétesz kezelésére
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning

Also Published As

Publication number Publication date
EP1397148A2 (de) 2004-03-17
CA2438063A1 (en) 2002-09-06
US20020197331A1 (en) 2002-12-26
JP2004521127A (ja) 2004-07-15
PT1397148E (pt) 2006-11-30
DE60214849D1 (de) 2006-11-02
US20050214385A1 (en) 2005-09-29
WO2002067953A2 (en) 2002-09-06
ES2271242T3 (es) 2007-04-16
DE60214849T2 (de) 2007-04-26
WO2002067953A3 (en) 2002-11-21
CN1512887A (zh) 2004-07-14
EP1397148B1 (de) 2006-09-20

Similar Documents

Publication Publication Date Title
DE60214849D1 (de) Chromium/biotin behandlung von dyslipidemia
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
TR200102962T2 (tr) Yeni tedavi metodu.
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
EP1576956A3 (de) Chromium/Biotin Behandlung von Typ-II Diabetes
BRPI0409716A (pt) derivados de 2-acilamino-4-feniltiazol, seu preparo e sua aplicação em terapêutica
DE69831576D1 (de) Chromium/biotin behandlung von typ-ii diabetes
BRPI0009719B8 (pt) processo de tratamento
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
SE9101815D0 (sv) Behandling av sjukdom foerbunden med hiv-infektioner
BR0115045A (pt) Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
MY139368A (en) Novel cyclohexyl sulphones
EP1666064A4 (de) Mittel zur behandlung von erkrankungen im zusammenhang mit immunoglobulin-gen-translokation
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
DE50204475D1 (de) Präparationen von vitamin e in kombination mit afamin
PL367630A1 (en) Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
Roberts A New Root for an Old Crux, Ps. XXII 17c
RU2000117903A (ru) Способ лечения хронического гастрита и язвенной болезни двенадцатиперстной кишки
RU2004102562A (ru) Способ лечения ограниченной склеродермии
RU98113874A (ru) Способ лечения угревой болезни у женщин
UA30769A (uk) Спосіб лікування онкологічних захворювань
RU2002109392A (ru) Способ лечения больных псориазом
RU2003126422A (ru) Спсооб лечения сладж-синдрома у больных хроническим бекскаменным холецистиом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397148

Country of ref document: EP

REN Ceased due to non-payment of the annual fee